About the Phase 2b Study 1 The phase 2b study was a 26-week, randomized, placebo-controlled study comparing the effects of four doses (1 mg, 5 mg, 10 mg, 15 mg) of Lilly's novel long-acting dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist to dulaglutide 1.5 mg and placebo in people with type 2 diabetes
Glucagon receptor activation increases fat oxidation
Reasons for the Label Expansion The FDAs new approval is based on the cardiovascular outcomes from the SELECT trial
Zhou, S., Yan, J., Song, K
Body Composition (Beta), part of Labs & Scans, gives an AI photo estimate of your body fat % and muscle mass with a confidence level and a 35% margin of error, and you can import a DEXA scan
This is a different situation entirely from a self-administering patient managing severe symptoms alone